The prevalence of chronic respiratory disease is rising, with more than 30 million cases in the US and over 500 million cases worldwide. Nearly 226,000 people are diagnosed with lung cancer every year. Although the lungs are highly accessible for delivering therapies, biological barriers such as the complex branched anatomy, disease-related airway narrowing, mucociliary clearance, alveolar macrophage uptake pose a formidable challenge to effective drug delivery.
The Menon Lab is developing drug delivery systems with unique biomimetic coatings and cargoes that can overcome these barriers for sustained drug delivery. We are also harnessing our expertise in targeted drug delivery to develop therapeutic formulations that can target and bind to disease-specific markers in lung disease, thus delivering therapies precisely to the areas of interest.
